Stellar Biotechnologies & Life Diagnostics Announce Agreement for Stellar Brand KLH ELISA Test Kits

PORT HUENEME, CA and WEST CHESTER, PA--(Marketwire - Oct 26, 2011) - Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) and Life Diagnostics, Inc. are pleased to announce they have entered into an exclusive manufacturing and supply agreement. Life Diagnostics (www.lifediagnostics.com) is a leader in the manufacture and sale of ELISA kits, purified biomarkers and antibodies for cardiovascular, inflammation, immunotoxicity and immunology research. Stellar Biotechnologies (www.StellarBiotech.com) is the world leader in sustainable manufacture of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin).

Under the agreement, Life Diagnostics will utilize Stellar's high-quality KLH to develop and manufacture Stellar brand KLH ELISA test kits for the detection of anti-KLH antibodies, for use in the growing immunotoxicity and immunology research markets.

This collaboration is expected to meet the increasing need among pharmaceutical researchers for improved test sensitivity, product consistency and analytical performance. Stellar will supply all aquaculture-derived KLH required for production of the ELISA test kits. Life Diagnostics will manufacture the ELISA test kits, and will work closely with Stellar in the commercial marketing and sale of these products. Initially, the agreement covers six different Stellar KLH ELISA products.

Life Diagnostics' CEO Christopher Chadwick said, "Our agreement with Stellar Biotechnologies reinforces Life Diagnostics' commitment to providing the highest quality products and specialized reagents to global biopharmaceutical and biotechnology customers. We are pleased to be working with Stellar's diagnostic team and look forward to producing a premium product line under the Stellar brand."

Stellar CEO Frank Oakes commented, "As the market leader in the manufacture and commercialization of ELISA test kits for immunology research, Life Diagnostics is an excellent partner for Stellar. We share a common interest in manufacturing the highest quality products and Life's long-standing expertise in developing leading ELISA products for the preclinical market may lead to further synergies. Stellar will also offer KLH immunizing products for use with the new KLH ELISA test kits. The Stellar KLH product line provides pharmaceutical researchers with a spectrum of consistent, standardized, quality reagents and materials. We look forward to offering these products to the research and clinical markets in early 2012."

Life Diagnostics Inc. is a leading manufacturer of ELISA kits, purified biomarkers and antibodies for cardiovascular, inflammation, immunotoxicity and immunology research.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacture of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). KLH is an important immune stimulating protein that is ideal for use in human and animal vaccines and diagnostic products. Stellar KLH products are used in research and clinical markets, and represent the Company's growing position as the only sustainable, long-term source for pharmaceutical KLH. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high quality, GMP grade KLH.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.